IFN-γ/Doxorubicin Complex Nanoparticles for Enhancing Therapy in the Context of Human Ovarian Carcinoma

The cytokine interferon gamma (IFN-γ) and doxorubicin mono-therapy has been approved by the Food Drug Administration (FDA) for treatment of tumors. importance IFN-γ in immune system lies its immunomodulatory effects, antitumor therapy inhibiting RNA DNA synthesis. In this work, role activity combination with was investigated. Meanwhile, used as a vehicle to load over immunotherapy chemotherapy synergistic therapy. IFN-γ/doxorubicin complex nanoparticles were prepared fusion method size approximately 13 nm low polydispersity index. release profile analyzed different pH ranges, it showed an enhanced acidic pH. ability induce human ovarian carcinoma cell (Skov 3) apoptosis evaluated cytotoxicity test. cellular uptake time-dependent, higher efficiency than free flow cytometry analysis fluorescence imaging. This work bridged utilize their potential activities, opening new avenues use clinical settings.